Search - tctmd.com

Displaying 361 - 380 of 400

Sort: Relevancy | Date

Presentation ARCH 2022

The Expanding Role of Advanced Imaging Modalities in Pre-procedural Planning in SHD Transcatheter Edge-to-Edge MitraClip Repair (TEER)

Presenter: James B. Hermiller

April 23, 2022

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

News Conference News STS 2022

CHOICE-MI: TMVR Mortality Much Lower With Newer Transseptal Devices

Todd Neale

February 03, 2022

News Conference News PCR London Valves 2021

MitraClip Cuts HF Hospitalizations in Real-World Registry: EXPAND

Shelley Wood

November 26, 2021

News Conference News PCR London Valves 2021

‘Reasonable’ Results With TMVR for Mitral Regurgitation: CHOICE-MI

Michael O'Riordan

November 25, 2021

News Conference News PCR London Valves 2021

Promising Early Results for TriClip in Tricuspid Regurgitation: bRIGHT Registry

Shelley Wood

November 24, 2021

Presentation TCT 2021

EXPAND G4: Core Laboratory Echocardiographic Outcomes From a Multicenter Study of a Fourth Generation TEER System to Treat Mitral Regurgitation

Presenter: Evelio Rodriguez

November 06, 2021

Presentation TCT 2021

Transseptal Chordal Repair Technology - The Promise and The Pitfalls

Presenter: Michael Rinaldi

November 06, 2021

Presentation TCT 2021

Early Outcomes with Beating Heart, Image-Guided Chordal Repair

Presenter: Konstantinos Koulogiannis

November 06, 2021

Presentation TCT 2021

Indirect Annuloplasty Technology- Lessons Learned Over the Past Decade

Presenter: Samir Kapadia

November 06, 2021

Presentation TCT 2021

Transcatheter Annuloplasty - Can it Replicate Surgery

Presenter: Scott Lim

November 06, 2021

Presentation TCT 2021

TEER in “Yellow Light” zone: Insights from Global Experience

Presenter: Molly Szerlip

November 06, 2021

Presentation TCT 2021

Limitations of TEER and Justification for Additional Transcatheter Repair Concepts

Presenter: Georg Nickenig

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Presenter: Ori Ben-Yehuda

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Presenter: Joanna Chikwe

November 05, 2021

Presentation TCT 2021

Pro: TEER Is the Optimal Therapy TODAY!

Presenter: Saibal Kar

November 05, 2021

Presentation TCT 2021

New Insights From COAPT

Presenter: Gregg Stone

November 05, 2021

Presentation TCT 2021

Emerging Data From the TVT and STS Mitral Registries

Presenter: Paul Sorajja

November 05, 2021

Presentation TCT 2021

What’s New in the 2020 Valvular Heart Disease Guidelines for Primary and Secondary MR?

Presenter: Robert Bonow

November 05, 2021

Presentation TCT 2021

Who Is the Ideal Candidate for TEER? Clinical and Anatomical Considerations

Presenter: Jason Rogers

November 04, 2021

Advertisement

The Expanding Role of Advanced Imaging Modalities in Pre-procedural Planning in SHD Transcatheter Edge-to-Edge MitraClip Repair (TEER)

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

CHOICE-MI: TMVR Mortality Much Lower With Newer Transseptal Devices

MitraClip Cuts HF Hospitalizations in Real-World Registry: EXPAND

‘Reasonable’ Results With TMVR for Mitral Regurgitation: CHOICE-MI

Promising Early Results for TriClip in Tricuspid Regurgitation: bRIGHT Registry

EXPAND G4: Core Laboratory Echocardiographic Outcomes From a Multicenter Study of a Fourth Generation TEER System to Treat Mitral Regurgitation

Transseptal Chordal Repair Technology - The Promise and The Pitfalls

Early Outcomes with Beating Heart, Image-Guided Chordal Repair

Indirect Annuloplasty Technology- Lessons Learned Over the Past Decade

Transcatheter Annuloplasty - Can it Replicate Surgery

TEER in “Yellow Light” zone: Insights from Global Experience

Limitations of TEER and Justification for Additional Transcatheter Repair Concepts

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Pro: TEER Is the Optimal Therapy TODAY!

New Insights From COAPT

Emerging Data From the TVT and STS Mitral Registries

What’s New in the 2020 Valvular Heart Disease Guidelines for Primary and Secondary MR?

Who Is the Ideal Candidate for TEER? Clinical and Anatomical Considerations

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content